The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunologic and clinical outcomes of perfluoroalkyl substances (PFAS) exposure in solid tumors treated with pembrolizumab.
 
Charles Jeffrey Tan
No Relationships to Disclose
 
Wenjiang Zhang
No Relationships to Disclose
 
Zhihui Liu
No Relationships to Disclose
 
Ben Wang
No Relationships to Disclose
 
Giselle Boukhaled
No Relationships to Disclose
 
Simone Stone
Research Funding - EMD Serono (Inst)
 
Jeffrey Bruce
No Relationships to Disclose
 
Stephenie Prokopec
No Relationships to Disclose
 
Aaron Hansen
Consulting or Advisory Role - Bayer; Full-Life technology; Janssen; Merck
Speakers' Bureau - Astellas Scientific and Medical Affairs Inc; Janssen; MSD Oncology
Research Funding - Advancell (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Full-Life Technologies (Inst); Fusion Pharmaceuticals (Inst); Janssen (Inst); Macrogenics (Inst); Merck (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer
 
Philippe Bedard
Honoraria - Boehringer Ingelheim
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bicara Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); LegoChem Biosciences (Inst); Lilly (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); ProteinQure (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Zymeworks (Inst)
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo/UCB Japan; Janssen Oncology; Lilly; Relay Therapeutics
 
Stephanie Lheureux
Honoraria - AstraZeneca; Eisai; GlaxoSmithKline; Merck; Roche/Genentech
Consulting or Advisory Role - Abbvie; AstraZeneca; Gilead Sciences; GlaxoSmithKline; Merck; Repare Therapeutics; Roche/Genentech; Seagen; Zai Lab
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Merck (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Schrodinger (Inst)
Travel, Accommodations, Expenses - GlaxoSmithKline (Inst)
 
Anna Spreafico
Consulting or Advisory Role - BeiGene; Bristol-Myers Squibb; GlaxoSmithKline; Merck
Research Funding - Alentis Therapeutics (Inst); Alkermes (Inst); ALX Oncology (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Replimune (Inst); Roche (Inst); Seagen (Inst); SERVIER (Inst); Symphogen (Inst); Teva (Inst); Treadwell Therapeutics (Inst)
 
Albiruni Abdul Razak
Consulting or Advisory Role - Alexion Pharmaceuticals; Boehringer Ingelheim; Clinical Research Malaysia; EMD Serono; Inhibrx; Medison; UpToDate
Research Funding - 23 and Me; Abbisko Therapeutics (Inst); Abbvie; Adaptimmune; Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Biosciences (Inst); Daiichi Sankyo; Deciphera; Frontier Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline; Intensity Therapeutics (Inst); Iterion Therapeutics; Karyopharm Therapeutics; Kelun (Inst); Medilink Therapeutics (Inst); Merck; Neoleukin Therapeutics; Novartis (Inst); Pfizer; Polaris (Inst); Rain Therapeutics; Roche/Genentech; Symphogen; Synox (Inst)
Expert Testimony - EMD Serono/Merck; Medison
 
Lillian Siu
Leadership - Treadwell Therapeutics (I)
Consulting or Advisory Role - Aktis Oncology; Amgen; Arvinas; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Daiichi Sankyo/UCB Japan; EMD Serono; Gilead Sciences; GlaxoSmithKline; Incyte; LTZ Therapeutics; Marengo Therapeutics; Merck; Navire; Nerviano Medical Sciences; Pangea; Pangea; Roche; Systimmune; Systinn; Tubulis GmbH; Velivago; Voronoi Health Analytics
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/UCB Japan (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); LegoChem Biosciences (Inst); Loxo/Lilly (Inst); Marengo Therapeutics (Inst); Medicenna (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Takara Bio (Inst)
Other Relationship - Canada's Drug Agency (CDA-AMC)
 
Eric Chen
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; GlaxoSmithKline; Incyte; Merck; Roche; Takeda
Research Funding - 1Globe Health Institute (Inst); AstraZeneca/MedImmune (Inst); BNT (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Mirati Therapeutics (Inst); Nouscom (Inst); Ono Pharmaceutical (Inst); Pfizer; Repare Therapeutics (Inst); Roche Canada (Inst)